[Form 4] Mineralys Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Mineralys Therapeutics (MLYS) Form 4: CFO and Secretary reported option exercises and share sales on 11/11/2025. He exercised options for 20,547 shares at $10.2, 34,414 at $16, 44,079 at $14.25, and 6,613 at $15.44. Same day, he executed multiple open-market sales, including 38,900 shares at a weighted-average price of $45.9277 and 32,718 at $46.8848, with other sales reported at weighted-average prices between $41.6522 and $46.8848.

Following the transactions, he directly beneficially owned 19,396 shares. The filing also notes that since his last ownership report, 83,598 shares were transferred to an ex-spouse pursuant to a domestic relations order.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levy Adam Scott

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD,

SUITE F200

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO and Secretary

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/11/2025		M		20,547	A	$10.2	53,814(1)	D
Common Stock	11/11/2025		M		34,414	A	$16	88,228	D
Common Stock	11/11/2025		M		44,079	A	$14.25	132,307	D
Common Stock	11/11/2025		M		6,613	A	$15.44	138,920	D
Common Stock	11/11/2025		S		1,015	D	$42	137,905	D
Common Stock	11/11/2025		S		11,295	D	$41.8709(2)	126,610	D
Common Stock	11/11/2025		S		1,561	D	$42.6794(3)	125,049	D
Common Stock	11/11/2025		S		12,952	D	$41.6522(4)	112,097	D
Common Stock	11/11/2025		S		8,485	D	$42.3404(5)	103,612	D
Common Stock	11/11/2025		S		4,142	D	$43.5015(6)	99,470	D
Common Stock	11/11/2025		S		8,456	D	$45.1805(7)	91,014	D
Common Stock	11/11/2025		S		38,900	D	$45.9277(8)	52,114	D
Common Stock	11/11/2025		S		32,718	D	$46.8848(9)	19,396	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$10.2	11/11/2025		M			20,547	(10)	02/13/2035	Common Stock	20,547	$0	135,674(11)	D
Stock Option	$16	11/11/2025		M			34,414	(12)	02/09/2033	Common Stock	34,414	$0	20,662(13)	D
Stock Option	$14.25	11/11/2025		M			44,079	(12)	02/13/2034	Common Stock	44,079	$0	91,592(14)	D
Stock Option	$15.44	11/11/2025		M			6,613	(12)	03/17/2033	Common Stock	6,613	$0	4,888(15)	D

Explanation of Responses:

1. Since the date of the Reporting Person's last ownership report, 83,598 shares of common stock were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.4500 to $42.2800. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.5100 to $42.9150. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.

4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $41.0550 to $42.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.

5. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.1000 to $43.0400. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

6. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.1700 to $44.0500. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.

7. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.4700 to $45.4600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.

8. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.4800 to $46.4725. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.

9. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.4900 to $47.3600. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.

10. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following the date of grant.

11. Since the date of the Reporting Person's last ownership report, 13,779 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

12. The stock option vests as to 25% of the total number of shares of common stock subject to the option on the first anniversary of the grant date, and as to 1/48th of the total number of shares of common stock subject to the option on each monthly anniversary thereafter.

13. Since the date of the Reporting Person's last ownership report, 42,442 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

14. Since the date of the Reporting Person's last ownership report, 64,329 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

15. Since the date of the Reporting Person's last ownership report, 8,499 stock options were transferred to an ex-spouse pursuant to a domestic relations order. The Reporting Person no longer reports as beneficially owned any securities owned by his ex-spouse.

Remarks:

	/s/ Adam Levy	11/13/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did MLYS’s CFO report on the latest Form 4?

He exercised stock options and sold shares on 11/11/2025, then directly beneficially owned 19,396 shares.

How many options did the MLYS CFO exercise and at what prices?

He exercised 20,547 at $10.2, 34,414 at $16, 44,079 at $14.25, and 6,613 at $15.44.

What were the reported sale prices for MLYS shares?

Sales were reported at weighted-average prices ranging from $41.6522 to $46.8848, including blocks at $45.9277 and $46.8848.

How many shares did the MLYS CFO own after the transactions?

He directly beneficially owned 19,396 shares after the reported transactions.

Were there any share transfers related to a domestic relations order?

Yes. Since the last report, 83,598 shares were transferred to an ex-spouse pursuant to a domestic relations order.

What is the officer’s relationship to Mineralys Therapeutics (MLYS)?

He is the company’s CFO and Secretary.